{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-014662","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.539170+00:00","generated_at":"2026-06-17T09:03:23.872854+00:00","sec_items":["2.02","5.03","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Femasys reports 2022 net loss of $11.4M, revenue up 2.2% to $1.2M","bullets":["Net loss of $11.4M ($0.96 per share) vs $7.5M loss in 2021; cash $12.96M expected to fund into Q1 2024.","Revenue $1.21M (+2.2% YoY); gross margin fell to 63.4% from 68.6%.","R&D expenses rose 42% to $5.81M; G&A expenses rose 27% to $5.43M.","Commercial launches of FemCath (tubal evaluation) and FemCerv (tissue sampler) in late 2022.","Clinical progress: FemBloc Stage 2 enrollment complete; FemaSeed pivotal trial 25% enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-014662","json":"https://secwatch.observer/filing/0001140361-23-014662.json","markdown":"https://secwatch.observer/filing/0001140361-23-014662.md","text":"https://secwatch.observer/filing/0001140361-23-014662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/brhc10050619_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:03:23.872854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd58de3bc39b0c2657046ad878c0ca8739c9f898","claim":"FEMASYS INC reported financial results for year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Femasys Inc. announced its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b8154ebe7924073222763dbc2ed732376e524e1d","claim":"FEMASYS INC: Reduced stockholder meeting quorum requirement to 33.4% (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, the Board of Directors of Femasys Inc. amended Section 5 of Article I of Femasys Inc.’s Amended and Restated Bylaws to reduce the quorum requirement for any meeting of stockholders to 33.4%.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}